EGFR and glioblastoma: Epigenome and transcriptome analyses using cell lines and pathological samples have shown that EGFR mutations remodel the activated enhancer landscape in glioblastoma, which promotes a more aggressive tumor phenotype through FOXG1- and SOX9-dependent transcriptional regulatory networks (Liu et al., 2015).